MBX Biosciences News

MBX Biosciences Shares Are Trading Higher on Possible Continued Strength After the Company Announced Results From Its Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of MBX 1416 Yesterday.

BenzingaJan 8 08:26 ET

J.P. Morgan Maintains MBX Biosciences(MBX.US) With Buy Rating

Moomoo NewsJan 8 06:31 ET · Ratings

MBX Biosciences, Inc. (MBX) Receives a Buy From J.P. Morgan

TipRanksJan 8 06:28 ET

MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action

BenzingaJan 7 11:47 ET

Express News | Mbx Biosciences Inc - 1416 Generally Well-Tolerated With Favorable Safety Profile

ReutersJan 7 07:00 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaJan 2 16:05 ET

Earnings Scheduled For December 19, 2024

BenzingaDec 19, 2024 03:32 ET

MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireDec 18, 2024 08:00 ET

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism

BenzingaDec 2, 2024 09:06 ET

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...

BenzingaNov 18, 2024 08:19 ET

Express News | Mbx Biosciences : Look Forward to Sharing Full-Topline Results of Mbx 1416 Program in Early January 2025

ReutersNov 18, 2024 08:03 ET

Express News | Mbx Biosciences Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia

ReutersNov 18, 2024 08:00 ET

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

GlobeNewswireNov 18, 2024 08:00 ET

MBX Biosciences | 10-Q: Quarterly report

SECNov 7, 2024 08:33 ET · Announcements

MBX Biosciences | 8-K: MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

SECNov 7, 2024 08:13 ET

Express News | Mbx Biosciences: Strong Cash Position, With $277.1 Mln Expected to Support Operations Into Mid-2027

ReutersNov 7, 2024 08:09 ET

MBX Biosciences Reports Q3 EPS ($2.78), Consensus ($2.72)

TipRanksNov 7, 2024 08:08 ET

MBX Biosciences 3Q Research and Development Expenses $16.7M >MBX

Dow JonesNov 7, 2024 08:07 ET

Earnings Flash (MBX) MBX BIOSCIENCES Posts Q3 Loss $-2.78 Per Share

MT NewswiresNov 7, 2024 08:04 ET

Express News | Mbx Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

ReutersNov 7, 2024 08:00 ET